Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Express Scripts
Colorcon
McKesson
Farmers Insurance
Merck
Daiichi Sankyo
Johnson and Johnson
Julphar

Generated: June 22, 2018

DrugPatentWatch Database Preview

Pernix Ireland Pain Company Profile

« Back to Dashboard

What is the competitive landscape for PERNIX IRELAND PAIN, and when can generic versions of PERNIX IRELAND PAIN drugs launch?

PERNIX IRELAND PAIN has one approved drug.

There are thirteen US patents protecting PERNIX IRELAND PAIN drugs.

There are one hundred and fifty-two patent family members on PERNIX IRELAND PAIN drugs in thirty-four countries.

Summary for Pernix Ireland Pain
International Patents:152
US Patents:13
Tradenames:1
Ingredients:1
NDAs:1
Patent Litigation for Pernix Ireland Pain: See patent lawsuits for Pernix Ireland Pain

Drugs and US Patents for Pernix Ireland Pain

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pernix Ireland Pain ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-002 Oct 25, 2013 RX Yes No 9,333,201 ➤ Try a Free Trial ➤ Try a Free Trial
Pernix Ireland Pain ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-001 Oct 25, 2013 RX Yes Yes 9,713,611 ➤ Try a Free Trial Y ➤ Try a Free Trial
Pernix Ireland Pain ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-004 Oct 25, 2013 RX Yes No 9,265,760 ➤ Try a Free Trial ➤ Try a Free Trial
Pernix Ireland Pain ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-002 Oct 25, 2013 RX Yes No 9,421,200 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for PERNIX IRELAND PAIN drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Capsules 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, and 50 mg ➤ Subscribe 2014-02-26

Non-Orange Book US Patents for Pernix Ireland Pain

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,119,163 Nanoparticulate and controlled release compositions comprising cefditoren ➤ Try a Free Trial
6,730,325 Multiparticulate modified release composition ➤ Try a Free Trial
9,522,147 Treating pain in patients with hepatic impairment ➤ Try a Free Trial
7,580,712 Wireless high-speed data network planning tool ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
US Department of Justice
Dow
Mallinckrodt
Harvard Business School
Johnson and Johnson
Merck
UBS
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.